Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 5.3%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) dropped 5.3% on Friday . The stock traded as low as $11.18 and last traded at $11.24. Approximately 25,113 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 367,410 shares. The stock had previously closed at $11.87.

Wall Street Analysts Forecast Growth

Separately, BMO Capital Markets restated an “outperform” rating and issued a $15.00 price objective on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Centessa Pharmaceuticals Price Performance

The company has a quick ratio of 8.00, a current ratio of 8.00 and a debt-to-equity ratio of 0.32. The firm has a market cap of $1.11 billion, a P/E ratio of -7.21 and a beta of 1.38. The business has a fifty day moving average of $10.68 and a 200 day moving average of $8.27.

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 51,160 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the transaction, the insider now owns 71,525 shares in the company, valued at $849,717. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Harris Rotman sold 4,267 shares of Centessa Pharmaceuticals stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.10, for a total transaction of $34,562.70. Following the completion of the transaction, the senior vice president now owns 62,625 shares in the company, valued at $507,262.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Karen M. Anderson sold 51,160 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the sale, the insider now owns 71,525 shares of the company’s stock, valued at $849,717. The disclosure for this sale can be found here. 11.54% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently bought and sold shares of CNTA. Octagon Capital Advisors LP lifted its position in Centessa Pharmaceuticals by 333.2% during the fourth quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock worth $16,398,000 after acquiring an additional 1,584,500 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Centessa Pharmaceuticals by 25.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock worth $18,313,000 after acquiring an additional 580,500 shares during the last quarter. Acuta Capital Partners LLC acquired a new stake in Centessa Pharmaceuticals during the third quarter worth approximately $2,092,000. Morgan Stanley lifted its position in Centessa Pharmaceuticals by 1,810.6% during the fourth quarter. Morgan Stanley now owns 315,135 shares of the company’s stock worth $977,000 after acquiring an additional 298,641 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Centessa Pharmaceuticals by 34.1% during the fourth quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock worth $8,882,000 after acquiring an additional 283,469 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.